Health News

Teva CEO promises to reshape, refocus company

NEW YORK (Reuters) - Teva Pharmaceutical Industries’ new Chief Executive Jeremy Levin promised on Tuesday to reshape the company into “the most indispensable medicines company in the world” and to provide significant value to its shareholders along the way.

Jeremy Levin, chief executive officer of Teva Pharmaceuticals Industries Ltd., looks on as his company begins trading on the floor of the New York Stock Exchange, May 30, 2012. REUTERS/Brendan McDermid

At a meeting in New York with investors and analysts, Levin, who took over as CEO in May, said Teva would sustain “profitable growth” through 2017 and beyond despite numerous challenges, such as the looming 2015 patent expiration of its most important branded product, the multiple sclerosis drug Copaxone. It accounts for about 20 percent of Teva sales and some 50 percent of its profits.

Investors were not immediately convinced and Teva shares fell 2 percent to close at $41.67 in New York.

The Israel-based company provided details about its cost-cutting plans, areas of focus going forward and new product development.

“Teva will be a reshaped company,” Levin said, and one that will be more transparent and accountable to Wall Street and its investors than it has been in the past. He said the dramatic transformation was underway.

“We have a completely new organization, a completely new management team,” Levin told Reuters after the meeting. “We have a process already ongoing inside the company. We are focused on credibility. We are focused on new products. We are changing our pipeline.”

Teva said it would continue to return money to shareholders through its dividend and $3 billion share buyback program, but it did not announce increases to either.

“I and other investors were hoping for a little more giveback of cash to investors ... a little short-term candy, but they took an approach of being conservative,” said Steven Tepper, an analyst with Harel Finance said.

But he said Levin accomplished his mission for the meeting.

“He really put forward his strategy and he’s going to make a big difference in the company,” Tepper said. “He’s turning a classical generic company with that extra bonus of Copaxone into a company that will be much more a real pharma company - more global, much more diverse and fully integrated.”

Levin said that in the future he does not want Teva to be as dependent on one product for a significant portion of its profits, and would accomplish that in part through growth of branded generics in emerging markets and its joint venture with Procter & Gamble Co on over-the-counter products.

But Levin, a former executive of Bristol-Myers Squibb Co., said the world’s largest maker of generic drugs would increasingly focus on bringing new medicines to market in its core areas of expertise, such as central nervous system disorders and respiratory diseases.

He said it also would focus on what Teva is calling new therapeutic entities, or NTEs. Those could be new uses, formulations, delivery methods or combinations of existing products.

Levin said China represents an enormous opportunity for future sales of respiratory disease products. “We haven’t yet scratched the surface of how to get into that part of the world,” he said.


Teva has 15 drugs in late-stage development and another 13 programs in mid-stage trials, but has discontinued 12 other pipeline programs that did not fit its new strategy.

The company has $10 billion available for business development over the next five years, it said.

It took a step toward adding to its portfolio of branded medicines earlier on Tuesday by announcing a deal for worldwide rights to an experimental pain drug being developed by Xenon Pharmaceuticals, a biotech company founded by Michael Hayden, Teva’s new chief scientific officer .

Hayden said NTEs, as they come from proven effective medicines, would provide high returns with much lower risks than developing new molecules. The company set a goal of approving development of 10-15 NTEs in 2013 and getting them to market beginning in 2016.

Hayden was particularly enthusiastic for the prospects of Teva’s experimental multiple sclerosis drug laquinimod, a neuroprotective medicine with potential to address progressive as well as relapsing MS.

It could hit the European market next year, but U.S. regulators have asked for another Phase III study before considering the drug for the world’s largest market. That two-year trial is just beginning.

Hayden sees the possibility of combining laquinimod with Copaxone or other drugs to better treat MS as well as address other neurodegenerative disorders such as Alzheimer’s disease, ALS and Parkinson’s disease.

The company sees other prospects for extending Copaxone use beyond the patent expiration with a new, more convenient, three-times-a-week version compared with its current daily formulation. That could reach the market in 2014.


While Teva was built through a series of large acquisitions, Levin reiterated his desire for mid-sized or small transactions, whether through licensing deals, acquisitions or alliances with large pharmaceutical companies, somewhat mirroring the successful “string of pearls” strategy of deals and collaborations he implemented at Bristol-Myers.

Teva, whose shares have badly underperformed those of its rivals during the last two years, on Tuesday provided details of where its planned $1.5 billion to $2 billion in cost savings over the next five years would come from, such as $400 million to $700 million by centralizing global purchasing power. It sees another $150 million to $175 million in savings by shifting from many small production facilities to larger, more efficient manufacturing sites.

Levin said Teva would also continue to divest non-core assets, a process it began by selling its U.S. animal health business to Bayer for up to $145 million.

RBC Capital Markets analyst Shibani Malhotra said there was a lot of information to digest. “That said, Jeremy is a great leader and he’s got a great team together, so we remain confident on the Teva story longer term.”

Reporting by Bill Berkrot; Editing by Dan Grebler, Tim Dobbyn and Bernard Orr